COST EFFECTIVENESS ANALYSIS OF RECATICIMAB VERSUS TAFOLECIMAB FOR PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA IN CHINA
Author(s)
jiang chen chen, MS1, Li Hongchao, PhD1, Xin Guan, PhD2, Yinyin Jin, MS3, HU bingqi, MS3.
1China Pharmaceutical University, Nanjing, China, 2Dr., China Pharmaceutical University, Nanjing, China, 3Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lianyungang, China.
1China Pharmaceutical University, Nanjing, China, 2Dr., China Pharmaceutical University, Nanjing, China, 3Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lianyungang, China.
OBJECTIVES: This study aimed to evaluate the cost-effectiveness of recaticimab versus tafolecimab in patients with primary hypercholesterolemia in China.
METHODS: A 10-state Markov model with a 1-year cycle length was developed to estimate lifetime costs and quality-adjusted life-years (QALYs) from the perspective of the Chinese healthcare system. Clinical efficacy, defined as the reduction in low-density lipoprotein cholesterol (LDL-C) levels, was derived from a network meta-analysis. The risk of major cardiovascular events (including stroke, myocardial infarction, angina pectoris, and cardiovascular death) was predicted for each treatment arm based on the corresponding LDL-C reductions achieved. Cost inputs were obtained from both real-world data and publicly available local sources. Costs and QALYs were discounted at an annual rate of 4.5%. The robustness of the base-case results was assessed through deterministic sensitivity analysis (DSA), probabilistic sensitivity analysis (PSA), and scenario analyses.
RESULTS: Recaticimab was associated with 11.63 QALYs at a cost of CNY 11,478, whereas tafolecimab yielded 11.32 QALYs at a cost of CNY 11,648. Compared with tafolecimab, recaticimab provided an incremental gain of 0.30 QALYs and a cost saving of CNY 170 per patient, establishing it as the dominant strategy. Both DSA and PSA indicated that the results were generally robust to parameter uncertainties. Furthermore, scenario analyses, which varied the dosages and administration intervals of both agents, produced findings consistent with the base-case analysis.
CONCLUSIONS: Recaticimab represents a dominant and more cost-effective therapeutic option compared with tafolecimab for patients with primary hypercholesterolemia in China.
METHODS: A 10-state Markov model with a 1-year cycle length was developed to estimate lifetime costs and quality-adjusted life-years (QALYs) from the perspective of the Chinese healthcare system. Clinical efficacy, defined as the reduction in low-density lipoprotein cholesterol (LDL-C) levels, was derived from a network meta-analysis. The risk of major cardiovascular events (including stroke, myocardial infarction, angina pectoris, and cardiovascular death) was predicted for each treatment arm based on the corresponding LDL-C reductions achieved. Cost inputs were obtained from both real-world data and publicly available local sources. Costs and QALYs were discounted at an annual rate of 4.5%. The robustness of the base-case results was assessed through deterministic sensitivity analysis (DSA), probabilistic sensitivity analysis (PSA), and scenario analyses.
RESULTS: Recaticimab was associated with 11.63 QALYs at a cost of CNY 11,478, whereas tafolecimab yielded 11.32 QALYs at a cost of CNY 11,648. Compared with tafolecimab, recaticimab provided an incremental gain of 0.30 QALYs and a cost saving of CNY 170 per patient, establishing it as the dominant strategy. Both DSA and PSA indicated that the results were generally robust to parameter uncertainties. Furthermore, scenario analyses, which varied the dosages and administration intervals of both agents, produced findings consistent with the base-case analysis.
CONCLUSIONS: Recaticimab represents a dominant and more cost-effective therapeutic option compared with tafolecimab for patients with primary hypercholesterolemia in China.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE626
Topic
Economic Evaluation
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory)